BG
CAI

Bellevue Group’s Caris Life Sciences CAI Stock Holding History

Bellevue Group’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$114K Hold
6,418
– – ﹤0.01% 131
2026
Q1 		$115K Hold
6,418
– – ﹤0.01% 138
2025
Q4 		$173K Sell
6,418
-3,187
-33% -$89.8K ﹤0.01% 155
2025
Q3 		$291K Sell
9,605
-395
-4% -$12.6K 0.01% 126
2025
Q2 		$267K Buy
+10,000
New +$270K 0.01% 119

Other funds holding CAI

JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $27.2B AUM 43.16% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Bellevue Group's CAI Position: Q2 2026 in Review

Bellevue Group held its Caris Life Sciences (CAI) position steady in Q2 2026 at 6,418 shares worth $114K. The position accounts for ﹤0.01% of the portfolio, ranked #131.

Bellevue Group first reported a position in CAI in Q2 2025 and has held it in 5 quarters since. The position peaked at $291K in Q3 2025. 213 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Bellevue Group held 6,418 shares of Caris Life Sciences worth $114K as of Q2 2026.
  • Bellevue Group left its Caris Life Sciences share count unchanged in Q2 2026.
  • Caris Life Sciences made up ﹤0.01% of Bellevue Group's portfolio in Q2 2026, its #131 holding.
  • Bellevue Group first reported a position in Caris Life Sciences in Q2 2025 and has held it in 5 quarters since.
  • Bellevue Group's Caris Life Sciences position peaked at $291K in Q3 2025.
  • 213 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.